Pharming Group (NASDAQ:PHAR) Sets New 1-Year High – Here’s What Happened

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR)’s share price hit a new 52-week high during mid-day trading on Monday . The stock traded as high as $17.19 and last traded at $16.8550, with a volume of 22063 shares. The stock had previously closed at $15.43.

Analyst Ratings Changes

PHAR has been the topic of several recent research reports. Weiss Ratings raised shares of Pharming Group from a “sell (d+)” rating to a “hold (c-)” rating in a report on Saturday, October 25th. Zacks Research raised Pharming Group from a “hold” rating to a “strong-buy” rating in a report on Thursday. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $30.00.

Pharming Group Stock Up 12.4%

The stock has a market cap of $1.19 billion, a price-to-earnings ratio of -1,732.77 and a beta of 0.03. The business’s 50 day moving average is $14.30 and its 200-day moving average is $12.06. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.39 and a current ratio of 3.16.

Pharming Group (NASDAQ:PHAR) last posted its quarterly earnings data on Thursday, November 6th. The company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.05 by $0.05. Pharming Group had a net margin of 0.30% and a return on equity of 0.46%. The business had revenue of $97.30 million for the quarter, compared to the consensus estimate of $98.22 million. Pharming Group has set its FY 2025 guidance at EPS. On average, sell-side analysts predict that Pharming Group N.V. Sponsored ADR will post -0.2 EPS for the current fiscal year.

Hedge Funds Weigh In On Pharming Group

A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC boosted its holdings in shares of Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) by 8.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 52,147 shares of the company’s stock after acquiring an additional 4,150 shares during the period. Silverberg Bernstein Capital Management LLC owned 0.08% of Pharming Group worth $557,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 0.03% of the company’s stock.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.